Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...
New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...
Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Novartis Intensifies Legal Action Against FDA Over Entresto Generic Approval
Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...
Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%
Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...
Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...
Hengrui Pharmaceuticals Launches Phase II Trial for SHR7280 to Treat Uterine Fibroids
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...
HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China
HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...
GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval
GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...
Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...
Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...
Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...
Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China
Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...
Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China
The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...
Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...
Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China
Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the...
Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC
Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...
China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...